Snehal Patel Buys 1,500 Shares of Greenwich LifeSciences (NASDAQ:GLSI) Stock

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel bought 1,500 shares of the business’s stock in a transaction that occurred on Monday, July 27th. The stock was purchased at an average price of $13.62 per share, with a total value of $20,430.00. Following the completion of the purchase, the chief executive officer directly owned 5,610,702 shares of the company’s stock, valued at $76,417,761.24. This represents a 0.03% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Snehal Patel also recently made the following trade(s):

• On Wednesday, July 29th, Snehal Patel bought 700 shares of Greenwich LifeSciences stock. The stock was purchased at an average cost of $13.10 per share, with a total value of $9,170.00.
• On Thursday, July 23rd, Snehal Patel purchased 2,500 shares of Greenwich LifeSciences stock. The shares were acquired at an average price of $13.14 per share, for a total transaction of $32,850.00.
• On Friday, July 24th, Snehal Patel acquired 1,100 shares of Greenwich LifeSciences stock. The stock was acquired at an average price of $12.88 per share, with a total value of $14,168.00.

Greenwich LifeSciences Stock Performance

NASDAQ:GLSI opened at $14.02 on Friday. The company has a 50-day moving average of $21.07 and a 200-day moving average of $24.12. The company has a market capitalization of $205.79 million, a price-to-earnings ratio of -8.93 and a beta of 1.40. Greenwich LifeSciences, Inc. has a 52 week low of $7.78 and a 52 week high of $34.10.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Bank of America Corp DE lifted its stake in shares of Greenwich LifeSciences by 22.3% in the 4th quarter. Bank of America Corp DE now owns 7,262 shares of the company’s stock valued at $82,000 after purchasing an additional 1,322 shares during the period. Rhumbline Advisers grew its stake in shares of Greenwich LifeSciences by 48.7% during the first quarter. Rhumbline Advisers now owns 9,673 shares of the company’s stock worth $92,000 after purchasing an additional 3,168 shares during the period. Wells Fargo & Company MN grew its stake in shares of Greenwich LifeSciences by 109.6% during the fourth quarter. Wells Fargo & Company MN now owns 7,845 shares of the company’s stock worth $165,000 after purchasing an additional 4,102 shares during the period. Strs Ohio bought a new stake in Greenwich LifeSciences in the first quarter valued at about $177,000. Finally, Jane Street Group LLC bought a new stake in Greenwich LifeSciences in the fourth quarter valued at about $203,000. Institutional investors own 4.16% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Greenwich LifeSciences in a research note on Friday, May 15th. HC Wainwright raised their target price on Greenwich LifeSciences from $50.00 to $69.00 and gave the stock a “buy” rating in a research report on Tuesday, July 21st. Finally, Wall Street Zen lowered Greenwich LifeSciences from a “hold” rating to a “sell” rating in a research note on Saturday, June 6th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $57.00.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc (NASDAQ: GLSI) is a clinical-stage biotechnology company focused on the development of novel immune modulators for the treatment of cancer and autoimmune diseases. The company’s product pipeline includes candidates engineered to activate or regulate key components of the innate and adaptive immune systems, with programs advancing through preclinical and early-stage clinical studies.

Headquartered in Greenwich, Connecticut, Greenwich LifeSciences conducts its research and development activities primarily in the United States.